CRP and head and neck cancer: For example, a CRP flare defined as a sharp CRP increase in the first weeks after starting treatment, followed by CRP decrease to below baseline, has been associated with ICI treatment response in NSCLC, head and neck cancer, metastatic urothelial carcinoma, and RCC [43–46].